Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Somatostatin Receptor Type 2 Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 22:43
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Pipeline Review, H2 2016’, provides in depth analysis on Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711799-somatostatin-receptor-type-2-srif1-or-sstr2-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2) 
- The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Complete report details @ https://www.wiseguyreports.com/reports/711799-somatostatin-receptor-type-2-srif1-or-sstr2-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 5 
Introduction 6 
Report Coverage 6 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Overview 7 
Therapeutics Development 8 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Products under Development by Stage of Development 8 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Products under Development by Therapy Area 9 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Products under Development by Indication 10 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Pipeline Products Glance 11 
Late Stage Products 11 
Early Stage Products 12 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Products under Development by Companies 13 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Products under Development by Universities/Institutes 15 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Therapeutics Assessment 17 
Assessment by Monotherapy/Combination Products 17 
Assessment by Mechanism of Action 18 
Assessment by Route of Administration 20 
Assessment by Molecule Type 22 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Companies Involved in Therapeutics Development 24 
Amryt Pharma plc 24 
Boehringer Ingelheim GmbH 25 
Crinetics Pharmaceuticals, Inc. 26 
Ipsen S.A. 27 
OctreoPharm Sciences GmbH 28 
Progenics Pharmaceuticals, Inc. 29 
Strongbridge Biopharma plc 30 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Drug Profiles 31 
AP-102 – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
COR-005 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Edotreotide Labeled Yttrium 90 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
FX-125L – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
lanreotide acetate – Drug Profile 39 
Product Description 39 
Mechanism Of Action 39 
R&D Progress 39 
OPS-201 – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Dormant Projects 46 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Discontinued Products 49 
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Featured News & Press Releases 50 
Jul 27, 2016: Supplemental Application Filed for Somatuline in Japan for Additional Indication of Neuroendocrine Tumors 50 
Jun 04, 2016: Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome 50
Jun 02, 2016: Ipsen Announces Data Presentations of Somatuline Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting 51 
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology 52 
Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium 53 
Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumors 54 
May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting 54 
Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain 55 
Apr 14, 2015: MHRA approves Ipsen’s Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumors 56 
Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium 57 
Dec 16, 2014: Ipsen’s Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors 57 
Nov 06, 2014: Ipsen Announces FDA Approval of a New Delivery Device for Somatuline Depot (lanreotide) Injection 58 
Sep 01, 2014: Ipsen Announces Acceptance of Filings for Somatuline in the Treatment of GEP-NET1s in the US with Priority Review and in Europe 59 
Jul 16, 2014: New England Journal of Medicine Publishes Ipsen’s Somatuline CLARINET Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors 59 
Jul 01, 2014: Ipsen submits marketing authorization applications in the US and Europe for Somatuline (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors 60 
Appendix 61 
Methodology 61 
Coverage 61 
Secondary Research 61 
Primary Research 61 
Expert Panel Validation 61 
Contact Us 61 
Disclaimer 62

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711799

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.